Roivant Sciences Ltd. (ROIV)
| Market Cap | 8.36B |
| Revenue (ttm) | 129.13M |
| Net Income (ttm) | 4.81B |
| Shares Out | 727.95M |
| EPS (ttm) | 5.89 |
| PE Ratio | 1.95 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,902,848 |
| Open | 11.31 |
| Previous Close | 11.31 |
| Day's Range | 11.24 - 11.51 |
| 52-Week Range | 8.61 - 13.06 |
| Beta | 1.24 |
| Analysts | Strong Buy |
| Price Target | 17.69 (+53.96%) |
| Earnings Date | Nov 12, 2024 |
About ROIV
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human mon... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price forecast is $17.69, which is an increase of 53.96% from the latest price.
News
Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Ben Zimm...
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, No...
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant ha...
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
BASEL, Switzerland and LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced its previously undisclosed pipeline program mosliciguat, a potential first-in-clas...
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
WALTHAM, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Pulmovant, a Roivant (Nasdaq: ROIV) company, today announced the presentation of data from the proof-of-concept Phase 1b ATMOS1 study during the ERS ...
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Monday, Immunovant, Inc. IMVT reported results from the Phase 2a trial of batoclimab in Graves' Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much ...
Roivant Provides Update on Graves' Disease Development Program
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported...
Top Stocks Near Their 200-Day SMA
The 200-day Simple Moving Average is an important technical indicator that can signal potential bullish sentiment and breakout opportunities for stocks. The 200-day SMA can also act as support or resi...
Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
Roivant Sciences stock has risen significantly since my initial coverage in 2022, with a positive market response to fiscal year 2025 Q1 earnings. Roivant operates by creating "nimble subsidiaries to ...
Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q1 2025 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Conference ...
The 'Undercovered' Dozen From June 1-6
The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered al...
Roivant Sciences: Executing On Huge Buyback Program With More To Come
Roivant Sciences' stock is undervalued with a market cap of $8.37 billion and $6 billion in cash. The company holds stakes in biotech companies worth billions, including Immunovant and Arbutus. Geneva...
Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Conference Call May 30, 2024 8:00 AM ET Company Participants Abby Beier - Principal, Strategic Finance Matt Gline - Chief Executive Officer Frank ...
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, an...
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, Ma...
Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
BASEL, Switzerland & LONDON & NEW YORK--(BUSINESS WIRE)--Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and aut...
Roivant's anti-inflammatory drug succeeds in mid-stage study
Roivant Sciences said on Tuesday its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study, sending the biotech firm's shares up...
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
BASEL, Switzerland and LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 2 study (NEPTUNE) evalua...
Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Roivant Sciences Ltd. has seen a slight gain of 10% in its stock over the past 10 months, since my "buy" recommendation last May. The company has a differentiated drug development pipeline targeting m...
Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a ...
Roivant Sciences: Why Its 'Vant' Biotech Model Is A Buy
Roivant Sciences operates with an innovative business model through its subsidiaries, specializing in specific therapeutic areas such as immuno-dermatology and autoimmune disorders. Notable achievemen...